| Document |
Document Title |
|
WO/2001/021613A1 |
A process for the preparation of cyclic lactic acid oligomers, which comprises (i) the first heating step of condensing lactic acid through dehydration by heating under such conditions of pressure and temperature that by-product water ca...
|
|
WO/2001/014371A1 |
N-Heterocyclic derivatives of formula (Ya) are described herein, as well as other N-heterocycles, as inhibitors of nitric oxide synthase. Pharmaceutical compositions containing these compounds, methods of using these compounds as inhibit...
|
|
WO/2001/010816A2 |
The invention relates to substituted 2-dialkylaminoalkylbiphenyl derivatives, a method for the preparation thereof, drugs containing them and the use thereof for the production of drugs.
|
|
WO/2001/005743A1 |
The invention relates to substituted 3-amino-2-benzyl-1-phenyl-propane derivatives, to methods for producing them, to medicaments containing these compounds and to the use of these substances for producing medicaments.
|
|
WO/2001/002463A1 |
Catalyst composition based on (a) a Group VIII metal compound, (b) an anion, and (c) a ligand of the formula R?1¿R?2¿M?1¿-R?5¿-M?2¿R?3¿R?4¿, wherein R?1¿, R?2¿, R?3¿ and R?4¿ represent similar or different hydrocarbyl groups, ...
|
|
WO/2001/002391A2 |
Compounds of formula (I) and pharmaceutically acceptable salts thereof in which A is methylene or -O-; B is methylene or -O-; and g is 0, 1, 2, 3 or 4; R¿1? represents, halo, optionally substituted alkyl, optionally substituted alkoxy, ...
|
|
WO/2001/000545A1 |
Process for the heterogeneous and enantioselective hydrogenation of prochiral organic $g(a)-keto compounds with platinum as the catalyst in the presence of a soluble or immobilised chiral aromatic nitrogen base with at least one basic ni...
|
|
WO/2000/076957A1 |
N-Alkoxyalkyl-N,N-dialkylamine derivatives of general formula [1] or salts thereof, which exhibit antihypoxic, nerve protecting and nerve regeneration promoting effects and are useful as remedies for nerve degeneration diseases, wherein ...
|
|
WO/2000/075099A1 |
Processes by which 5-hydroxy-3-oxopentanoic acid derivatives useful as intermediates of drugs can be prepared from inexpensive and easily available raw materials under noncryogenic conditions. Specifically, a process for preparing 5-hydr...
|
|
WO/2000/073250A1 |
A process for treating a composition containing a substantial proportion of trimethylolpropane bis-monolinear formal (TMP-BMLF) or trimethylolethane bis-monolinear formal (TME-BMLF), e.g., a heavy ends residue obtained from the purificat...
|
|
WO/2000/073264A1 |
Compounds having formula (I), inhibit cellular proliferation. Processes for the preparation of the compounds, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds are disclosed.
|
|
WO/2000/069810A1 |
A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or preventio...
|
|
WO/2000/068221A1 |
The invention relates to salts of (4R-cis) -(1,1-dimethyl -ethyl) -6-(2-aminoethyl) -2,2-dimethyl -1,3-dioxane -4-acetate of formula (I) formed with organic acids. The new salts according to the invention are stable and can be easily pur...
|
|
WO/2000/067751A1 |
Compounds represented by formula (I): or a pharmaceutically acceptable salt or hydrate thereof, are disclosed. Pharmaceutical compositions and methods of treatment are also included.
|
|
WO/2000/066545A1 |
The invention concerns compounds of general formula (I) wherein: R¿1? represents either a hydrogen atom, or an amino group, or a C¿1?-C¿4? alkyl group, or a C¿1?-C¿6? alkoxycarbonyl group, or a -OH group; R¿2? represents either a C...
|
|
WO/2000/066577A2 |
A method of treating ocular hypotension, hypertension, hemorrhage, myocardial ischemia, angina pectoris, coronary contraction, cerebrovascular contraction after subarachnoidal hemorrhage, cerebral hemorrhage and asthma which comprises ad...
|
|
WO/2000/066556A1 |
This invention comprises compounds of formula (I), which are antagonists of the progesterone receptor, their preparation and utility.
|
|
WO/2000/064848A1 |
The invention relates to a method for the dihydroxylation of olefins using transition-metal catalysts for producing monofunctional, bifunctional and/or polyfunctional 1,2 diols of the formula (I): R?1¿R?2¿C(OH)-C(OH)R?3¿R?4¿. Accordi...
|
|
WO/2000/064844A1 |
The invention relates to a method for the asymmetric dihydroxylation of olefins, using osmium catalysts for producing monofunctional, bifunctional and/or polyfunctional chiral 1,2 diols of formula (I): R?1¿R?2¿C(OH)-C(OH)R?3¿R?4¿. Ac...
|
|
WO/2000/061573A1 |
The invention concerns novel benzodioxinones and a method for obtaining them. The inventive benzodioxinones correspond to the general formula (I) wherein: R¿1? to R¿6? are as described in Claim 1. The invention also concerns a method f...
|
|
WO/2000/059880A1 |
The present invention relates to cinnamide compounds of formula (I), in which at least one of R¿1? to R¿5? is a '$i(cis)-cinnamide' (a) or a '$i(trans)-cinnamide' (b) and the other variables are as defined in the claims, that are usefu...
|
|
WO/2000/058301A1 |
A compound of general formula (I) wherein X represents a hydrogen or halogen atom or a cyano, methyl, methoxy or phenylmethoxy group and/or R¿1? represents a hydrogen atom and R¿2? represents an alcanoyl group, a phenylalcanoyl group, ...
|
|
WO/2000/053547A1 |
The invention relates to a method of preparing surface-active alcohols and surface-active alcoholic ethers which are well suited for use as surface-active agents or for the preparation of surface-active agents. To this end, olefin mixtur...
|
|
WO/2000/052002A1 |
Compounds of Formula (I) wherein R¿2?, Y, X and n are as defined in the specification which compounds are useful in the treatment of disorders associated with serotonergic neuron-related diseases.
|
|
WO/2000/050390A1 |
The present invention relates to a novel class of organic molecules capable of inhibiting C-proteinase, and to their use to regulate, modulate and/or inhibit abnormal collagen formation as a therapeutic approach towards the treatment of ...
|
|
WO/2000/050415A1 |
A process for preparing glycerol carbonate easily and economically by reacting glycerol with urea.
|
|
WO/2000/049014A1 |
The invention concerns a process for the manufacture of tert-butyl (E)-(6-[2- 4-(4-fluorophenyl) -6-isopropyl-2-[ methyl (met hylsulfonyl) amino] pyrimidin-5-yl] vinyl}-(4R, 6S)-2,2-dimethyl [1,3-dioxan-4-yl) acetate, the novel starting ...
|
|
WO1996012697A9 |
The present invention features compounds of general formulae a), b), c), able to modulate one or more activities of an inorganic ion receptor and methods for treating diseases or disorders by modulating inorganic ion receptor activity. P...
|
|
WO/2000/047551A2 |
The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural an...
|
|
WO/2000/044731A1 |
The current invention discloses novel hydroxyamidino carboxylate derivatives useful as nitric oxide synthase inhibitors. Compounds of particular interest are defined by Formula (I) wherein X, Y, A, J, R?1¿, R?2¿ R?3¿, R?4¿, R?7¿ and...
|
|
WO/2000/044473A1 |
A method and device for purifying noxious gases are disclosed. In an operation of the device, noxious gases are discharged into purification liquid within a tower in the same direction as vortexes of the liquid, thus forming gas bubbles ...
|
|
WO/2000/043381A1 |
The invention relates to a method for producing high-purity dilactide giving a high yield. The inventive method consists of four steps: (1) an aqueous lactic acid solution is dehydrated in an azeotropic manner after an inert entrainer ha...
|
|
WO/2000/043382A1 |
A piperidine, tetrahydropyridine or piperazine derivative having formula (I), any of its enantiomers or any mixture thereof, or an acid addition salt thereof, wherein B is C¿1-10?-alkylene, C¿1-10?-alkenylene or C¿1-10?-alkynylene; X ...
|
|
WO/2000/041998A1 |
Propargylether derivatives of formula (I) including the optical isomers thereof and mixtures of such isomers, wherein R¿1? is hydrogen, alkyl, cycloalkyl or optionally substituted aryl, R¿2? and R¿3? are each independently hydrogen or...
|
|
WO/2000/039081A2 |
The present invention relates to novel cinnamide compounds that are useful for treating inflammatory and immune diseases, to pharmaceutical compositions containing these compounds, and to methods of inhibiting inflammation or suppressing...
|
|
WO/2000/039062A1 |
Compounds are provided of the formula for use in a range of liquid crystal display devices (formula I) wherein n may be 0, 1 or 2, A¿1?, A¿2?, A¿3? are independently chosen from 1,4-disubstituted benzene, 2,5-disubstituted pyridine, 2...
|
|
WO/2000/035858A1 |
The invention is concerned with novel N-(4-carbamimidoyl-phenyl)-glycine derivatives of formula (I), wherein R?1¿, E, X?1¿ to X?4¿ and G?1¿ and G?2¿ are as defined in the description and the claims, as well as hydrates or solvates a...
|
|
WO/2000/034264A1 |
A convenient, efficient and industrially favorable process for producing simvastatin which is useful as an HMG-coA reductase inhibitor. This process comprises deacylating lovastatin by treating with an inorganic base and a secondary or t...
|
|
WO/2000/025776A1 |
The present invention describes novel nitrosated and/or nitrosylated nonsteroidal antiinflammatory compounds, and novel compositions comprising at least one nitrosated and/or nitrosylated nonsteroidal antiinflammatory compound, and, opti...
|
|
WO/2000/018756A1 |
A crude lactide in solid form or at least partially molten form is brought into contact with ethanol to obtain a slurry mixture and then the solid is separated from the mixture to obtain a purified lactide of a high purity. A crude lacti...
|
|
WO/2000/018726A1 |
The present invention relates to a method for the production of trion-bis(oxime ether) derivatives of formula (I), wherein the substituents have the following meaning: R?1¿, R?3¿ represent unsubstituted, partially or totally halogenate...
|
|
WO/2000/018722A2 |
The present invention relates to new derivatives of 6-(4-phenylbutoxy)hexylamine having the general formula (I) wherein R¿1? is CHO, or CHOR¿3?OR¿4?, wherein R¿3? and R¿4? are independently C¿1?-C¿6? alkyl, aralkyl or can form cyc...
|
|
WO/2000/018757A1 |
Purified lactide having a high purity is obtained by bringing crude lactide in a solid state or at least partly molten state into contact with ethanol to give a mixture in the form of a slurry and then separating solid matters from the m...
|
|
WO/2000/017173A1 |
The invention relates to compounds of formula (I) and their tautomeric and isomeric forms and salts, as well as to a method for producing said compounds and their use in medicines.
|
|
WO/2000/016766A1 |
A medical composition containing, as an active constituent, a nitroetheneamine derivative represented by formula (I) wherein R?1¿ is a hydrogen atom, an optionally substituted alkyl, alkenyl, alkinyl, cycloalkyl, cycloalkenyl, aryl or h...
|
|
WO/2000/014085A1 |
Oxygenic heterocyclic compounds represented by formula (I) or pharmacologically acceptable salts thereof: wherein m is an integer of 0 to 4; R?1¿, R?2¿, R?3¿, and R?4¿ are the same or different and each represents hydrogen, optionall...
|
|
WO/2000/012084A1 |
The present invention relates to novel geometrically restricted 2-indolinones and physiologically acceptable salts thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treat...
|
|
WO1999042460A9 |
A process for the production of optically enriched (R)- or (S)-albuterol or (R)- or (S)-albuterol salts by the resolution of a novel ketal derivative 2-(N-t-butylamino)-1-(+2,2-dimethyl-1,2-benzodioxin-6-yl) ethanol, with a chiral tartar...
|
|
WO/2000/009494A1 |
Processes for the preparation of 1,3-oxathiolane nucleosides are provided that include efficient methods for the preparation of the 1,3-oxathiolane ring and subsequent condensation of the 1,3-oxathiolane with a pyrimidine or purine base....
|
|
WO/2000/008011A1 |
A process for the preparation of optically active 2-[6-(hydroxymethyl)-1,3-dioxan-4-yl]acetic acid derivatives, which comprises subjecting an enolate prepared by reacting an acetate ester derivative with either a base or a zero-valent me...
|
